A potentially blinding disease called keratoconus may now be stopped and even reversed with a new process applying vitamin B2 eye drops and low-dose ultraviolet light to the diseased eye, according to a press release released by Robert Epstein, MD. The first FDA-monitored clinical trial in Illinois of what is called "corneal collagen cross linking" has begun and is enrolling under the direction of Dr. Epstein at the McHenry and Niles offices of Mercy Health System.
No comments:
Post a Comment